ARTICLE | Clinical News
Tigecycline: Phase III data
November 8, 2004 8:00 AM UTC
In an international Phase III trial in 817 patients, microbiological eradication rate was 91.3% in patients receiving tigecycline vs. 89.9% for patients receiving Primaxin imipenem and cilastatin (p<0...